Aelis Farma SA
PAR:AELIS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.8
13.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Aelis Farma SA
Long-Term Debt
Aelis Farma SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aelis Farma SA
PAR:AELIS
|
Long-Term Debt
€1.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€187.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€59.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
48%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€46.8m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Long-Term Debt
€86.2m
|
CAGR 3-Years
90%
|
CAGR 5-Years
45%
|
CAGR 10-Years
22%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Long-Term Debt
€40m
|
CAGR 3-Years
20%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Aelis Farma SA
Glance View
Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
See Also
What is Aelis Farma SA's Long-Term Debt?
Long-Term Debt
1.4m
EUR
Based on the financial report for Dec 31, 2023, Aelis Farma SA's Long-Term Debt amounts to 1.4m EUR.
What is Aelis Farma SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-4%
Over the last year, the Long-Term Debt growth was 0%. The average annual Long-Term Debt growth rates for Aelis Farma SA have been -30% over the past three years , -4% over the past five years .
You don't have any saved screeners yet
